…
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -38.45M | -47.80M | -36.17M | -25.65M | -18.06M |
| Minority interest | - | - | - | 0.00M | 0.00M |
| Net income | -32.02M | -40.53M | -30.68M | -21.41M | -13.84M |
| Selling general administrative | 7.29M | 8.53M | 7.05M | 5.95M | 5.18M |
| Gross profit | - | - | - | 0.00M | 0.00M |
| Reconciled depreciation | 0.73M | 0.94M | 0.89M | 0.72M | 0.37M |
| Ebit | -39.12M | -47.91M | -36.42M | -26.70M | -24.93M |
| Ebitda | -47.58M | -41.88M | -28.59M | -23.94M | -24.56M |
| Depreciation and amortization | -8.46M | 6.03M | 7.83M | 2.76M | 0.37M |
| Non operating income net other | - | - | - | 0.00M | 0.00M |
| Operating income | -39.12M | -47.91M | -36.42M | -26.70M | -19.13M |
| Other operating expenses | 43.72M | 45.36M | 32.95M | 25.68M | 22.03M |
| Interest expense | -9.86M | 4.98M | 6.70M | 0.99M | 0.00M |
| Tax provision | -6.43M | -7.27M | -5.49M | -4.24M | -4.22M |
| Interest income | 0.67M | 0.10M | 0.25M | 1.05M | 1.06M |
| Net interest income | 0.67M | 0.10M | 0.25M | 1.05M | 1.06M |
| Extraordinary items | - | - | - | 0.00M | 0.00M |
| Non recurring | - | - | - | 0.00M | 0.00M |
| Other items | - | - | - | 0.00M | 0.00M |
| Income tax expense | -6.43M | -7.27M | -5.49M | -4.24M | -4.22M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 43.72M | 45.36M | 32.95M | 25.68M | 22.03M |
| Cost of revenue | - | - | - | 0.00M | 0.00M |
| Total other income expense net | 0.67M | 0.10M | 0.25M | 1.05M | 2.90M |
| Discontinued operations | - | - | - | 0.00M | 0.00M |
| Net income from continuing ops | -32.02M | -40.53M | -30.68M | -21.41M | -13.84M |
| Net income applicable to common shares | -32.02M | -40.53M | -30.68M | -21.41M | -13.84M |
| Preferred stock and other adjustments | - | - | - | 0.00M | 0.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 27.81M | 58.25M | 77.47M | 107.79M | 70.27M |
| Intangible assets | 2.13M | 2.37M | 2.41M | 4.75M | 3.96M |
| Other current assets | - | 2.68M | 3.15M | 3.80M | 4.12M |
| Total liab | 12.92M | 19.75M | 11.93M | 8.56M | 6.75M |
| Total stockholder equity | 14.89M | 38.50M | 65.55M | 99.23M | 63.52M |
| Deferred long term liab | - | - | - | - | 0.00M |
| Other current liab | 9.10M | 14.26M | 9.68M | 5.61M | 3.50M |
| Common stock | 2.11M | 143.20M | 143.14M | 142.94M | 80.84M |
| Capital stock | 2.11M | 143.20M | 2.09M | 2.05M | 1.30M |
| Retained earnings | -207.71M | -180.57M | -149.73M | -110.59M | -80.06M |
| Other liab | - | 0.05M | 0.05M | 0.05M | 0.03M |
| Good will | - | - | - | - | 0.00M |
| Other assets | - | 0.10M | 2.60M | 0.04M | 0.05M |
| Cash | 17.23M | 41.91M | 60.26M | 87.36M | 51.96M |
| Total current liabilities | 12.68M | 19.31M | 11.72M | 8.15M | 6.18M |
| Net debt | -16.83M | -41.27M | -59.89M | -86.71M | -51.16M |
| Short term debt | 0.21M | 0.24M | 0.21M | 0.28M | 0.27M |
| Short long term debt | - | - | - | - | 0.00M |
| Short long term debt total | 0.40M | 0.64M | 0.37M | 0.65M | 0.81M |
| Other stockholder equity | 141.31M | 219.07M | 215.27M | 209.82M | 143.58M |
| Property plant equipment | - | 0.87M | 0.85M | 1.19M | 1.11M |
| Total current assets | 25.02M | 54.92M | 71.61M | 101.81M | 65.15M |
| Long term investments | - | - | - | - | 0.00M |
| Net tangible assets | - | 36.14M | 63.14M | 94.48M | 59.56M |
| Short term investments | - | - | - | - | 0.00M |
| Net receivables | 5.83M | 10.32M | 11.35M | 14.45M | 13.19M |
| Long term debt | - | - | - | - | 0.00M |
| Inventory | - | - | -3.15M | - | 0.00M |
| Accounts payable | 3.38M | 4.80M | 1.83M | 2.26M | 2.41M |
| Total permanent equity | - | - | - | - | 0.00M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00M |
| Accumulated other comprehensive income | 79.17M | 75.87M | 72.14M | 66.89M | 62.74M |
| Additional paid in capital | - | - | - | - | 0.00M |
| Common stock total equity | - | - | - | 2.05M | 1.30M |
| Preferred stock total equity | - | - | - | - | 0.00M |
| Retained earnings total equity | - | - | - | - | 0.00M |
| Treasury stock | - | - | - | - | -0.34M |
| Accumulated amortization | - | - | - | - | 0.00M |
| Non currrent assets other | - | - | 2.54M | - | 1.11M |
| Deferred long term asset charges | - | - | - | - | 0.00M |
| Non current assets total | 2.79M | 3.33M | 5.86M | 5.99M | 5.12M |
| Capital lease obligations | 0.40M | 0.64M | 0.37M | 0.65M | 0.81M |
| Long term debt total | - | - | - | - | 0.54M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 0.12M | -3.56M | -1.31M | -0.14M | -0.65M |
| Change to liabilities | 2.97M | -0.43M | -0.15M | -0.04M | 1.33M |
| Total cashflows from investing activities | 0.12M | -3.56M | -1.31M | -0.14M | -0.65M |
| Net borrowings | -0.23M | -0.30M | -0.30M | -0.20M | -0.20M |
| Total cash from financing activities | -0.16M | -0.10M | 61.80M | -0.05M | 0.21M |
| Change to operating activities | 0.75M | 4.52M | 2.10M | -2.06M | 2.14M |
| Net income | -32.02M | -40.53M | -30.68M | -21.41M | -13.84M |
| Change in cash | -18.35M | -27.09M | 35.39M | -25.01M | -9.73M |
| Begin period cash flow | 60.26M | 87.36M | 51.96M | 76.97M | 86.70M |
| End period cash flow | 41.91M | 60.26M | 87.36M | 51.96M | 76.97M |
| Total cash from operating activities | -23.16M | -23.82M | -21.62M | -23.83M | -12.22M |
| Issuance of capital stock | 0.07M | 0.00M | 66.58M | 0.12M | 0.00M |
| Depreciation | 0.73M | 0.94M | 0.89M | 0.72M | 0.37M |
| Other cashflows from investing activities | 0.64M | -2.50M | 0.32M | 1.12M | 0.97M |
| Dividends paid | - | - | - | 0.00M | 0.00M |
| Change to inventory | - | - | - | 0.00M | 0.00M |
| Change to account receivables | - | - | - | 0.00M | 0.00M |
| Sale purchase of stock | - | - | - | 0.12M | 0.21M |
| Other cashflows from financing activities | 0.12M | 0.20M | -4.48M | 0.03M | 0.21M |
| Change to netincome | 4.41M | 11.67M | 6.22M | -1.04M | -2.23M |
| Capital expenditures | 0.52M | 1.06M | 1.63M | 1.26M | 1.62M |
| Change receivables | - | - | - | 0.00M | 0.00M |
| Cash flows other operating | - | - | - | 0.00M | 0.00M |
| Exchange rate changes | - | - | - | 0.00M | 0.00M |
| Cash and cash equivalents changes | - | - | - | 0.00M | 0.00M |
| Change in working capital | 3.72M | 4.09M | 1.95M | -2.10M | 3.47M |
| Stock based compensation | 4.89M | 6.66M | 4.30M | 3.23M | 1.79M |
| Other non cash items | 5.95M | 12.28M | 7.41M | -0.02M | 0.20M |
| Free cash flow | -23.68M | -24.89M | -23.25M | -25.09M | -13.85M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NCNA NuCana PLC |
0.03 4.37% |
0.75 | - | - | - | 0.63 | 0.31 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Hugh Stephen Griffith | Founder, CEO & Exec. Director | 1968 |
| Mr. Donald Munoz | Chief Financial Officer | 1969 |
| Mr. David Harrison | Head of Translational Medicine | 1960 |
| Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. | Chief Medical Officer | 1957 |
| Prof. Christopher B. Wood FRCS, M.D., Ph.D. | Chief Medical Officer | 1946 |
| Ms. Theresa Bruce | Sr. VP of Clinical Operations | NA |
| Ms. Elisabeth Oelmann | Sr. VP of Medical & Clinical Devel. | NA |
| Martin Quinn | Company Sec. | NA |
| Mr. Hugh Stephen Griffith | Founder, CEO & Executive Director | 1968 |
| Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. | Chief Medical Officer | 1958 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.